DermTech, Inc. operates as a molecular diagnostics firm specializing in developing and commercializing innovative, non-invasive genomic tests designed to assist in the early detection and ongoing management of melanoma within the United States. Its flagship product, the DermTech Melanoma Test (DMT), offers a non-surgical method for improved melanoma detection, with further development underway for non-melanoma skin cancers. Complementing this, the DermTech Smart Sticker facilitates the non-invasive collection of skin samples, presenting a gentler alternative to traditional scalpel biopsies for suspicious lesions.
